Update on the clinical utility of fenofibrate in mixed dyslipidemias: mechanisms of action and rational prescribing

Abstract

Mixed dyslipidemia is a common lipid disorder characterized by the presence of an atherogenic lipoprotein phenotype due to abnormalities in various atherogenic and anti-atherogenic lipoproteins. Despite the link between the decrease of LDL-cholesterol by statin treatment and the prevention of cardiovascular disease, a high residual risk is observed in statin trials. This residual risk is partly explained by lipoprotein abnormalities other than LDL. Fenofibrate exerts a favorable effect on the atherogenic lipid profile of mixed dyslipidemia and can effectively reduce cardiovascular disease in patients with mixed dyslipidemia. Fenofibrate may offer important treatment alternatives as a second-line therapy in several circumstances: in combination with a statin for patients with mixed dyslipidemias not at goals on statin mono-therapy; in monotherapy for patients intolerant or with contraindication to statin therapy; and in combination with other drugs (ezetimibe, colesevelam) for patients with mixed dyslipidemias, known intolerance, or contraindication to statin and not at goals on fenofibrate monotherapy. However, the role of fenofibrate-statin therapy and of other therapies involving fenofibrate in cardiovascular risk reduction strategies remains to be established.

Keywords:

• fenofibrate
• mixed dyslipidemia
• triglycerides
• LDL-cholesterol
• HDL-cholesterol

Disclosures

The author reports having received grant/research support and/or honoraria from a consultant for Astra-Zeneca, Genfit, Genzyme, Kowa, Merck and Co, Merck-Schering-Plough, Novartis, Pfizer, Roche, Sanofi-Aventis, Solvay, and Takeda.